InvestorLens

ABOS — ACUMEN PHARMACEUTICALS INC

Public company

Sign in to save2 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying ABOS?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
67
Institutional Conviction
Strong distribution · 1 buying vs 2 selling last quarter
22
Macro Tailwind
Macro conditions are mixed for this sector
55
Why? — Evidence & Confidence ▾

Of 3 tracked investors who changed their ABOS position last quarter, 1 bought and 2 sold (33% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 55/100 in a Squeeze regime).

Supporting evidence
  • +1 tracked investor added or increased positions last quarter (Ken Griffin)
  • +2 tracked investors reported holding ABOS at their latest filing
  • +Macro Health is 55/100 in a Squeeze regime — historically acceptable for this sectorsource
Contradicting evidence — always shown
  • −2 tracked investors reduced or exited last quarter (1 reduced, 1 sold out)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 8/20/2026.

About ACUMEN PHARMACEUTICALS INC (ABOS)

ACUMEN PHARMACEUTICALS INC (ABOS) appears in the most recent 13F filings of 2 tracked institutional investors. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $11M. Across recent filings, tracked investors recorded 3 new positions, 5 increased, 9 reduced, and 1 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in ABOS

44
/100
Mixed Activity
Added / Increased8
Reduced9
Exited1
BearishBullish
Crowded Trade Score™

How many top investors track ABOS

13
/100
Undiscovered
2investors

Only 2 tracked investors report this position.

UndiscoveredCrowded
151015+

ABOS Ownership Composition

How ACUMEN PHARMACEUTICALS INC is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
100% of tracked value
Institutions
2
tracked investors
Total Reported
$298.1K
combined 13F value
Types1
  • Multi-Strategy / Quant100.0%
Multi-Strategy / Quant(2)
100.0%

Tracked investors currently reporting ABOS

1 tracked investor has since exited this position — listed separately below.

  • Izzy EnglanderJun 30, 2026
    Millennium Management
    Shares
    60.6K
    Value
    $161.8K
    % Portfolio
    0.00%
  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    51K
    Value
    $136.3K
    % Portfolio
    0.00%

Previously held ABOS

These investors reported ABOS in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

InvestorFirmLast reported sharesValue thenLast held
Steve CohenPoint72 Asset Management67.4K$159KMar 31, 2026

Recent activity

Frequently asked questions

How many institutional investors hold ABOS?
2 tracked institutional investors disclosed a position in ABOS (ACUMEN PHARMACEUTICALS INC) in their most recent 13F filing.
Who is the largest institutional holder of ABOS?
Izzy Englander, Millennium Management, holds the largest disclosed position in ABOS, valued at $11M.
Did institutional ownership of ABOS increase or decrease?
Across recent 13F filings, tracked investors recorded 3 new positions, 5 increased, 9 reduced, and 1 fully exited ABOS.
Where does this ABOS ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.